NASDAQ$AONC
American Oncology Network In · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported strong revenue growth driven by patient encounter growth and strategic acquisitions
American Oncology Network, Inc. reported a 20.0% increase in revenue to $364.3 million for the first quarter of 2024, driven by a 7.1% growth in patient encounters and strategic acquisitions. The company's net loss before non-controlling interest was $24.9 million, and Adjusted EBITDA was $2.0 million.
- Revenue increased by 20.0% to $364.3 million compared to the prior year quarter.
- Patient encounters grew by 7.1% compared to the prior year quarter.
- 17 new providers were added to the AON platform, expanding in Texas and Maryland markets.
- Net cash provided by operating activities was $45.1 million, driven by the deferral of $48.3 million of drug payments due to the Change Healthcare issue.
Headline financials
Revenue & EPS history
American Oncology Network · Revenue · Quarterly
$434M
Forward guidance
AONC did not provide specific forward guidance in this earnings report. The report focuses on Q1 2024 results and strategic initiatives.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 1 quarterly earnings reports
-1.0%
Avg return
Earnings day
-7.8%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+3.3%
Q1 2025
Best reaction
-4.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2025 | +3.3% | -0.8% | -11.7% | |
| Q3 2024 | +1.1% | -14.8% | +3.7% | |
| Q2 2024 | -0.9% | — | — | |
| Q1 2024 | — | — | — | |
| Q4 2023 | -4.4% | — | — | |
| Q3 2023 | -4.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro